US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
BHP Shares Fall as Jansen Potash Project Costs Surge 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Trump Says Anthropic No Longer Seen as National Security Threat 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
CVS Health is projecting another year of solid earnings growth, announcing that its expected 2026 profit will surpass both Wall Street forecasts and its own 2025 earnings outlook. The update, shared during the company’s investor day, underscores the steady progress of its ongoing turnaround strategy led by Chief Executive David Joyner.
Joyner emphasized that CVS has delivered on its commitments throughout the year and will now concentrate on improving consumer experiences and rebuilding trust—an area he described as a major challenge in today’s healthcare marketplace. As part of this effort, the company unveiled a new consumer app designed to integrate CVS services and offer new revenue opportunities for partners.
Shares of CVS climbed nearly 5% to $80.17 in morning trading following the announcement, extending a year of strong market performance. The stock has surged more than 70% in 2025 as the company implemented sweeping changes, including cost reductions, exits from underperforming markets, and enhancements to leadership to restore investor confidence.
Chief Financial Officer Brian Newman highlighted the company’s strong finish to 2025, stating that CVS expects “another year of strong earnings growth in 2026.” The company forecast adjusted earnings between $7.00 and $7.20 per share for 2026, slightly above consensus expectations of $7.16 per share.
While CVS anticipates up to $400 billion in revenue next year—short of analysts’ projected $419.26 billion—the company expects growth momentum to be driven by improved margins in its Aetna insurance arm and CVS Caremark pharmacy benefit management business. CVS also reiterated plans to exit the Affordable Care Act insurance market in 2026 due to rising medical costs.
Additionally, CVS raised its 2025 profit guidance to between $6.60 and $6.70 per share, marking its fourth increase this year. Analysts at Leerink Partners noted that CVS’ near-term performance supports a strong long-term recovery story for the healthcare conglomerate.
